pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,047 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1566Endpoints1227BioSpace568Fierce Biotech562BioPharma Dive467raps194onclive165fda recalls
therapy area
allOncology10451Rare Disease2758Immunology2463Cardiology2288Hematology1887Pulmonology1875Vaccines
  • FDA appoints permanent heads for CDER and CBER amid pending commissioner confirmation
    The Department of Health and Human Services announced that Michael Davis, MD, PhD, and Karim Mikhail will become the permanent directors of the Centers for Drugs Evaluation and Research and the Cen…
    Fierce Biotech · 1mo agoRegulatoryNeutral↗ source
  • Researchers urge FDA to adopt EMA-style drug rejection letter disclosures
    The FDA began publishing letters that explain why a drug application was denied in September 2025, marking a significant transparency shift. Researchers argue that the agency’s current disclosures…
    Endpoints · 1mo agoRegulatoryNeutral↗ source
← prev
page 26 of 82
next →
103
fda medwatch93
globenewswire health73
fda press54
1646
Psychiatry & CNS1107
Ophthalmology871
Endocrinology & Metabolism691
Pain656
Nephrology645
  • NodThera rebrands as Rezera and targets Phase 3 trial in 2027
    NodThera, a biotech focused on the NLRP3 inflammatory pathway for about ten years, announced a strategic shift. The company said it will rebrand itself as Rezera and is preparing to launch a pivot…
    Endpoints · 1mo agoNeutral↗ source
  • Evommune's MRGPRX2 antagonist fails second Phase 2b trial in atopic dermatitis
    Evommune reported that its experimental small-molecule antagonist of the MRGPRX2 receptor did not meet its primary endpoints in a Phase 2b study in patients with atopic dermatitis. The study, cond…
    Endpoints · 1mo agoNegative readoutNegative↗ source
  • FDA grants accelerated approval to AstraZeneca’s Etcamah, enabling ctDNA-guided therapy for HR-positive breast cancer
    The FDA issued an accelerated approval for AstraZeneca’s oral selective estrogen receptor degrader camizestrant, to be sold as Etcamah, marking a rare departure from its advisory committee’s recomm…
    Fierce Biotech · 1mo agoApprovalPositive↗ source
  • AstraZeneca’s IL-33 antibody tozorakimab earns FDA priority review after COPD trial cuts exacerbations by up to 34%
    AstraZeneca’s R&D chief medical officer Sharon Barr said the company’s latest data on its IL-33 inhibitor represents an internal “science success story.” The results have earned the drug a priority…
    Fierce Biotech · 1mo agoPositive readoutPositive↗ source
  • Boston Scientific recalls spinal cord stimulator leads after over 1,000 serious injuries
    Boston Scientific announced a recall of its Infinion CX spinal cord stimulation leads after the FDA classified the action as the most serious level. The recall, issued June 17, covers all unused l…
    Fierce Biotech · 1mo agoCRLNegative↗ source
  • Amgen reports positive lung cancer trial results for Imdelltra combined with checkpoint inhibitor
    Amgen announced that its T-cell engager candidate Imdelltra, when used together with a checkpoint inhibitor, showed a clinical benefit in patients with advanced lung cancer. The trial data indicat…
    Endpoints · 1mo agoPositive readoutPositive↗ source
  • FDA finalizes Krazati withdrawal while Wegovy trial shows positive results in children 6-12
    Regulators have officially completed the withdrawal of Krazati, a drug that was being developed for second-line treatment of colorectal cancer. The FDA’s final action ends the product’s availabilit…
    Endpoints · 1mo agoRegulatoryNeutral↗ source
  • Roivant's inhaled drug mosliciguat achieves positive Phase 2 results in interstitial lung disease
    Roivant Sciences reported that its inhaled candidate mosliciguat has successfully completed a Phase 2 trial in patients with interstitial lung disease. The study met its primary endpoint, showing a…
    Endpoints · 1mo agoPositive readoutPositive↗ source
  • Spyre Therapeutics reports positive Phase 2 results for anti-IL-23 antibody SPY003 in ulcerative colitis
    Spyre Therapeutics announced that its anti‑IL‑23 antibody, SPY003, achieved its primary and secondary goals in a Phase 2 ulcerative colitis study. The trial, part A of the Skyline program, enrolled…
    Fierce Biotech · 1mo agoPositive readoutPositive↗ source
  • BMS CAR-T therapy arlo-cel meets primary endpoint in pivotal multiple myeloma trial
    Bristol Myers Squibb reported that its GPRC5D-directed CAR-T cell therapy, arlo-cel, achieved the primary endpoint in the pivotal Quintessential trial for multiple myeloma. The study enrolled pati…
    Fierce Biotech · 1mo agoPositive readoutPositive↗ source
  • Pharvaris reports injectable-like efficacy from once-daily oral pill for rare genetic disease
    Pharvaris announced that its experimental oral formulation of deucrictibant achieved efficacy comparable to injectable versions in a once-daily pill. The drug is an extended-release version intend…
    Endpoints · 1mo agoPositive readoutPositive↗ source
  • Sanofi presents detailed asthma trial data while AstraZeneca reports positive COPD results at ERS 2026
    At the European Respiratory Society meeting in Barcelona, Sanofi disclosed detailed findings from its asthma trial, building on earlier indications of efficacy. The data highlighted specific endpo…
    Endpoints · 1mo agoPositive readoutPositive↗ source
  • Schrödinger launches Tectora Therapeutics with $55 million Series A to target immunology and inflammation
    Schrödinger announced the formation of Tectora Therapeutics, a new biotech focused on immune‑mediated diseases, backed by a $55 million Series A financing round. As part of the launch, Schrödinger…
    Fierce Biotech · 1mo agoDealPositive↗ source
  • Sandoz announces $300 million biosimilar factory in Slovenia and plans to expand pipeline sevenfold
    Sandoz, the generic and biosimilar division of Novartis, said it will invest $300 million to build a new biosimilar manufacturing facility in Slovenia. The company also announced that its newly cr…
    Endpoints · 1mo agoDealPositive↗ source
  • Bristol Myers reports Phase 2 success for GPRC5D‑directed CAR‑T therapy
    Bristol Myers announced positive Phase 2 results for its GPRC5D‑directed CAR‑T therapy aimed at treating multiple myeloma. The study demonstrated encouraging efficacy signals, adding to the growing…
    Endpoints · 1mo agoPositive readoutPositive↗ source
  • Inhibrx reports promising mid-stage data for OX40 agonist and plans vaccine combos early next year
    Inhibrx Biosciences announced that its OX40 agonist showed encouraging activity in a mid-stage trial involving immunogenic cancers. The data suggest the agent may also enhance responses when paire…
    Endpoints · 1mo agoPositive readoutPositive↗ source
  • BrainChild Bio raises $116 million to fund pivotal pediatric brain tumor CAR-T trial
    BrainChild Bio, a Seattle-based biotech, announced it has secured $116 million in financing to support a pivotal clinical trial of its CAR-T therapy aimed at pediatric brain tumors. The funding ro…
    Endpoints · 1mo agoDealPositive↗ source
  • Diabetes cell-therapy firms Sernova and Seraxis announce merger
    Two diabetes-focused cell-therapy companies, Sernova and Seraxis, have agreed to merge after decades of developing treatments for the disease. The combined company aims to pool resources and exper…
    Endpoints · 1mo agoDealNeutral↗ source
  • Pharvaris reports 83% drop in hereditary angioedema attacks in phase 3 trial, FDA decision pending
    Pharvaris announced that its oral bradykinin B2 receptor antagonist, deucrictibant, met the primary goal in a second phase 3 study. The trial, called CHAPTER-3, enrolled 85 patients with three for…
    Fierce Biotech · 1mo agoPositive readoutPositive↗ source
  • Novartis shares tumble after late-stage failure of Avidity-acquired drug
    Novartis announced that its late-stage trial of a drug it acquired from Avidity did not meet its primary endpoints. The setback follows a recent disappointment in a heart disease study, adding pres…
    Endpoints · 1mo agoNegative readoutNegative↗ source
  • BMC Medical recalls 20,160 Luna G3 APAP devices over firmware defect, class I recall
    BMC Medical Co., Ltd. announced a recall of its Luna G3 APAP (Model LG3600) devices that were distributed in the United States after identifying a firmware defect. The defect was linked to firmwar…
    fda medwatch · 1mo agoRegulatoryNegative↗ source
  • Novartis' del-desiran fails primary endpoint in phase 3 Harbor trial for myotonic dystrophy type 1
    Novartis announced that its experimental therapy del-desiran did not meet the primary endpoint in the phase 3 Harbor trial, which evaluated improvement in video hand opening time in patients with m…
    Fierce Biotech · 1mo agoNegative readoutNegative↗ source
  • Inhibrx reports 9.6-month median PFS for OX40 agonist combo in phase 2 head-neck cancer trial
    Inhibrx Biosciences presented updated data from its phase‑2 HexAgon study of the hexavalent OX40 agonist INBRX‑106 combined with Merck’s Keytruda in patients with untreated metastatic or unresectab…
    Fierce Biotech · 1mo agoPositive readoutPositive↗ source